Weight loss outcomes vary by agent and dose: high-dose semaglutide (2.4mg/Wegovy) has shown mean weight reductions of approximately 15% in the STEP clinical trials, while liraglutide (3mg/Saxenda) typically achieves 5-8% weight loss
FD has received occasional consulting fees/honoraria and travel grants from BMS-Pfizer Alliance, Amgen, AstraZeneca, Bayer, Bouchara-Recordati, Bristol Myers Squibb, Boehringer Ingelheim, Menarini, Merck Sharp & Dohme, Novartis, Novo Nordisk, Organon, Pfizer, Sanofi, and Servier
Mounjaro interacts with the brain region that controls temperature Research suggests that Mounjaro may directly affect our bodys temperature control system
Peer-reviewed clinical research has evaluated Retatrutide in adults with obesity and has reported meaningful changes in body weight in trial settings